NRX Pharmaceuticals (NRXP) Receivables (2020 - 2026)

NRX Pharmaceuticals (NRXP) posted quarterly Receivables of $362000.0 for Q1 2026, up 124.84% quarter-over-quarter from $161000.0 in Q4 2025.

NRX Pharmaceuticals (NRXP) Receivables (2020 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported Receivables for 6 consecutive years, with $362000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Receivables changed N/A year-over-year to $362000.0; the TTM figure through Mar 2026 stood at $362000.0 (changed N/A YoY), while the FY2025 annual figure was $161000.0, changed N/A from the prior year.
Receivables advanced to $362000.0 in Q1 2026 per NRXP's latest filing, from $161000.0 in the prior quarter.
Across five years, Receivables topped out at $3.3 million in Q3 2025 and bottomed at $6000.0 in Q1 2023.
Historically, Receivables has averaged $461666.7 across 5 years, with a median of $12000.0 in 2023.
Annual changes were most pronounced in 2023 — Receivables tumbled 95.56% — and 2024, when it changed 0.0%.
NRX Pharmaceuticals' Receivables stood at $270000.0 in 2022, then sank by 95.56% to $12000.0 in 2023, then slumped by 50.0% to $6000.0 in 2024, then soared by 2583.33% to $161000.0 in 2025, then jumped by 124.84% to $362000.0 in 2026.
Business Quant data shows NRXP's Receivables at $362000.0 in Q1 2026, $161000.0 in Q4 2025, and $3.3 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	139.40 Bn	131.54 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	86.13 Bn	78.13 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	65.58 Bn	60.40 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.23 Bn	53.09 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	42.18 Bn	37.08 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.61 Bn	28.30 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	27.97 Bn	9.58 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.55 Bn	26.39 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-	-
10	NRX Pharmaceuticals	132.90 Mn	106.20 Mn	426,000.00	412,000.00

Download Data